Active, not recruitingNCT07459127
Multicenter Retrospective Cohort of Pulmonary NUT Carcinoma
Studying NUT midline carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Three Gorges Hospital of Chongqing University
- Intervention
- Standard-of-care anticancer treatment (retrospective)(other)
- Enrollment
- 150 target
- Eligibility
- All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Chongqing University Three Gorges Hospital, Chongqing, Chongqing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07459127 on ClinicalTrials.govOther trials for NUT midline carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07050186Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT CarcinomaNorthwestern University
- RECRUITINGPHASE1NCT05372640Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNational Cancer Institute (NCI)
- RECRUITINGNCT05265429Biology of Young Lung Cancer Study: The YOUNG LUNG StudyDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT05019716Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)